CompanyANTXNasdaqMenlo Park, CA

AN2 Therapeutics, Inc.

AN2 Therapeutics develops small-molecule therapeutics from its boron chemistry platform for hematologic diseases, infectious diseases, and oncology.

SEC EDGAR ClinicalTrials.gov an2therapeutics.com

10-QAug 11Latest SEC filing, period to Jun 30

Aug 11Latest story

August 2026

AN2 Therapeutics reports Q2 2026 results, updates timelines on three Phase 2 programs

Aug 11Quarterly updateAN2 Therapeutics, Inc.